Nuvation Bio Inc.
NUVB-WTDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Taletrectinib | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Frequently asked questions
What is in Nuvation Bio Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Nuvation Bio Inc.'s (NUVB-WT) pipeline across Phase 3. Its lead program is Taletrectinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nuvation Bio Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Nuvation Bio Inc. (NUVB-WT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NUVB-WT biotech catalysts?→
Add NUVB-WT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nuvation Bio Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.